L3VLUP
ProSign in

GRFS · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GRFSLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GRFS
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterGRFSLLY
Q3 20208 holders, $472m33 holders, $14.1bn
Q4 20207 holders, $477m29 holders, $17.3bn
Q1 20217 holders, $471m24 holders, $23.0bn
Q2 20216 holders, $442m24 holders, $27.8bn
Q3 20216 holders, $357m31 holders, $29.9bn
Q4 20215 holders, $301m31 holders, $34.7bn
Q1 20224 holders, $281m24 holders, $35.3bn
Q2 20225 holders, $406m33 holders, $42.7bn
Q3 20224 holders, $162m31 holders, $43.4bn
Q4 20224 holders, $304m31 holders, $46.6bn
Q1 20234 holders, $294m33 holders, $44.3bn
Q2 20235 holders, $391m37 holders, $59.6bn
Q3 20235 holders, $404m44 holders, $67.6bn
Q4 20235 holders, $510m45 holders, $73.6bn
Q1 20245 holders, $266m41 holders, $95.3bn
Q2 20245 holders, $249m43 holders, $110bn
Q3 20246 holders, $320m45 holders, $107bn
Q4 20243 holders, $185m46 holders, $93.9bn
Q1 20253 holders, $178m42 holders, $98.4bn
Q2 20255 holders, $341m43 holders, $93.2bn
Q3 20254 holders, $290m39 holders, $86.7bn
Q4 20253 holders, $240m41 holders, $123bn
Q1 20263 holders, $199m39 holders, $106bn
Q2 20261 holders, $162m44 holders, $132bn
GRFS

Grifols SA

Holders
6
Reported value
$320m
Buyers
3
Sellers
1

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 49 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GRFS (4)

Eisler Capital Management Ltd, Farallon Capital Management LLC, Harris Associates LP, Soros Fund Management LLC

Only LLY (43)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, and 18 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →